Akero Therapeutics, Inc. Marketable Securities
Akero Therapeutics, Inc. had Marketable Securities of $812.28 million as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Balance Sheet › Assets
us-gaap:MarketableSecurities · last filed 2025-11-07
- 2025-09-30: Marketable Securities $812.28M.
- 2025-06-30: Marketable Securities $865.80M.
- 2025-03-31: Marketable Securities $942.37M.
- 2024-12-31: Marketable Securities $457.59M.
| Period end | Marketable Securities | Marketable Securities as first filed |
|---|---|---|
| 2025-09-30 | $812.28M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $865.80M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $942.37M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $457.59M 10-Q · filed 2025-11-07 | |
| 2024-09-30 | $471.01M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $537.97M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $279.81M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $335.09M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $343.45M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $214.74M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $298.35M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $101.68M 10-K · filed 2024-02-29 | $292.18M 10-K · filed 2023-03-17 |
| 2022-09-30 | $130.46M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $154.79M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $129.44M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $154.04M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $189.19M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $223.87M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $224.44M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $239.17M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $239.23M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $89.06M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $110.77M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $125.25M 10-K · filed 2021-03-16 |